The Global CKD and Hypertension Pandemic affects 1.13 Billion people worldwide, inflicting death and suffering.
Global healthcare costs are estimated at over $500 Billion (1) a year.
Hypertension is one of the main causes of CKD - costing Medicare, in the USA alone,
over $84 billion (2,3) a year.
The only current solution, Dialysis, dramatically reduces patients' quality-of-life
– 5-year patient survival probability for all renal replacement therapy - 50.8% (4).
CureSpec was Founded in 2020.
Our first market-ready product, Nephrospec™ is intended for the interrelated treatment of:
- CKD (Chronic Kidney Disease)
- Hypertension (High Blood Pressure)
NephroSpec - Saving lives & costs
NephroSpec promotes new blood vessel formation and restores damaged tissue
function by means of its patented ShockWave technology.
We hold an Established, market-ready product, with a strong IP portfolio, which includes a granted U.S. patent,
a fully developed CE-Marked device & Promising preliminary clinical results.
CureSpec has an established Production facility, a Global distribution chain and an experienced management team.
Gaziano TA, Asaf B, S Anand, et.al. The global cost of non-optimal blood pressure. J Hypertens. 2009
Kramer A, Boenink R, Noordzij M, et al. The ERA-EDTA Registry Annual Report 2017 : a summary. 2020
Nephrospec - a medical device manufactured by Curespec.
Nephrospec - a safe, non-invasive shockwave device intended for the treatment of CKD and Hypertension
Nephrospec - promotes new blood vessel formation and restores damaged tissue function through its patented technology
Nephrospec - saves up to 80% of costs while easing suffering and needless loss of lives
Complementary solution to optimal medical care for CKD and hypertension
Kidney function improvement in weeks
Outpatient treatment delays onset of dialysis
Post Shockwave treatment
Curespec uses shockwave technology to produce a neovascularization affect on the kidneys.
Founder, Active Chairman
Mr. Spector has over 30 years experience in the international Medtech industry, having held top R&D management positions in medical instrument companies in Israel and the US. He holds a B.Sc. Degree in Mechanical Engineering from Ben-Gurion-University of the Negev, Israel.
Mr. Brandt is a Certified Public Accountant (CPA) from the Bar-Ilan University, and holds an MBA degree from the Hebrew University. Mr. Brandt has over 10 years of experience in financial management, including as a CFO in the private sector and as a Senior Auditor at Ernst & Young (EY).